BURLINGAME, California, September 10, 2020 (GLOBE NEWSWIRE) – Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinically staged biopharmaceutical company, today announced updated knowledge of its ongoing Phase 1 exam on the perspective of ICC-006 to provide a new immunotherapy technique for COVID-19 patients. The effects showed that all evaluable patients treated in the first two cohorts (0. 3 and 1. 0 mg CPI-006 dose) of the test produced significant anti-SARS- CoV-2 antibodies within seven days of receiving treatment, with antibody levels, adding impartial antibodies, often expanding up to 28 days In addition, all those patients were discharged from the hospital with clinical improvement and none experienced any protection related to the drug. The test completed recruitment in the third cohort (dose of 3. 0 mg of ICC-006) of five patients, and the overall examination is expected to recruit up to 30 patients.
Dr Miller added: “CPI-006’s unique immunotherapy technique for treating COVID-19 would possibly offer benefits over other developing treatments. Specifically, compared to passively administered monoclonal antibody techniques, we believe that CPI-006 can also cause B Mobile activation at much lower antibody dose levels and provides opposite activity to possible new mutant variants, as it works by activating the immune formula to generate a polyclonal anti-SRAS-CoV. Two antibodies. Based on this unique mechanism, we are considering the option of using ICC-006 earlier, adding in symptomatic outpatients and in combination with vaccination, in the hope that it may also limit or eliminate the need for booster injections and produce long-term immunity. “
Phase 1 CPI-006 COVID-19 Study Update The Phase 1 open-label study is expected to recruit up to 30 hospitalized COVID-19 patients with mild to moderate symptoms. Single patients will get a dose of CPI-006, with grades of 0 , 3, 1. 0, 3. 0, and 5. 0 mg / kg, expanding into 4 cohorts as the study progresses. Patients will obtain medications, treatments, and interventions according to popular COVID-19 remedial protocols for the duration of the study. The number one efficacy is the amendment of serum anti-SARS-CoV-2 immunoglobulin grades (IgM and IgG) from the initial price on day 28. The study will also read about protection and other clinical parameters, adding time to symptoms and duration of hospitalization.
The company submitted a manuscript describing the initial effects of the first two cohorts (five patients receiving a dose of 0. 3 mg and five patients receiving a dose of 1. 0 mg) of the test for publication online at medRxiv. org. of the patients was 64 years old (range 28 to 76 years) and all patients had comorities that expanded their threat of COVID-19: diabetes (4), high blood pressure (2), obesity (7) and/or cancer (2). The median duration of symptoms prior to the ICC-006 remedy was 8 days (range 1 to 21 days). Highlights of these 10 patients include:
Additional knowledge of this study is expected until the end of 2020, adding 3. 0 and 5. 0 mg cohort effects and longer cohort monitoring knowledge of 0. 3 and 1. 0 mg. The Society presented a imaginable presentation of the knowledge examination at the annual meeting of the Society for Cancer Immunotherapy (SITC) in November. In addition, if the study achieves its goals, Corvus contacts the FDA to publish a broader randomized study that could potentially be adapted to a critical study to help a regulatory filing for FDA approval.
To date, more than 90 cancer patients have been treated with CPI-006 in the Corvus Phase 1 / 1b study, at a dose of up to 24 mg / kg every 3 weeks. CPI-006 was well tolerated in these patients and evidence of B motile activation and lymphocyte trafficking was seen in patients receiving single doses as low as 1 mg / kg. The Corvus study showed that CPI-006 is related to an accumulation of memory B mobiles, the appearance of new B mobile clones and, in some patients, the production of new anti-tumor antibodies. These effects have been reported in the past in presentations at the Cancer Immunotherapy Society Annual Meeting in 2018 and 2019 and in a presentation at the American Society for Clinical Oncology Annual Meeting in 2019. The CPI-006 has been designed to binding to an epitope on an antigen known as CD73. This antigen is known to be related to lymphocyte migration and activation. CPI-006 binds to a region other than CD73 and behaves as an agonist that serves as a signal to activate certain immune mobiles. As noted above, CPI-006 binding affects B mobiles, T mobiles, and antigen presenting mobiles. The collection of adjustments observed is consistent with the progressive popularity of the antigen and the induction of an adaptive immune response.
About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus’ flagship product applicants are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and mobile immune activation. These product applicants are recently being investigated in phase 1b / 2 and phase 1 / 1b clinical trials in patients with a wide variety of complex forged tumors. Ciforadenant is being evaluated in a phase 1b / 2 successive expansion cohort trial examining its activity as monotherapy and in admixture with anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter phase 1 / 1b monotherapy clinical trial mixed with ciforadenant and pembrolizumab. The company’s third cancer clinical program, CPI-818, a small-molecule oral drug that selectively inhibits ITK, in a multicenter phase 1 / 1b clinical trial in patients with multiple types of mobile T lymphoma. The company is also comparing CPI-006 as a remedy for COVID-19 patients. For more information, visit www. corvuspharma. com.
About CPI-006CPI-006 is a resistant humanized monoclonal antibody that reacts with an express site on CD73. It demonstrated immunomodulatory activity leading to lymphocyte activation, induction of B-cell antibody production and effects on lymphocyte traffic. anti-CD73 antibodies in progression for cancer remedy, These antibodies have been reported to react with another region of CD73 and are designed to block the production of adenosine, which is not involved in the immunomodulatory processes observed with CPI-006ArrayCPI- 006 is in a Phase 1 study in patients with COVID-19 with the aim of expanding the immune reaction to SARS-CoV-2.
Forward-Looking Statements This press release comprises forward-looking statements, adding statements regarding the protection and forward-looking effectiveness of CPI-006, the company’s ability to expand and promote candidate products, and full clinical trials, adding the Company’s Phase 1 clinical trial. of CPI-006 for COVID-19. All statements other than forward-looking statements of fact contained in this press release are forward-looking statements. These statements come with words such as “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate”, “seek”, “will”, “possibly”, or similar expressions. Forward-looking statements are subject to a number of dangers and uncertainties, most of which involve matters or events beyond the control of the Company. The Company’s actual effects may also differ materially from those stated or implied in any forward-looking statement due to a number of points, adding, but not limited to, the hazards detailed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the Securities and Exchange Commission on July 30, 2020, in combination with other documents that would possibly be filed through the Company from time to time with the Securities and Exchange Commission, and Values. In particular, the following points, among others, may also cause effects that differ materially from those expressed or implied through those forward-looking statements: the ability of the company to demonstrate sufficient evidence of efficacy and protection in its test clinics in the IPC-006; the accuracy of the company’s estimates of its ability to initiate and / or complete clinical trials; the effects of preclinical studies may not be predictive of long-term effects; the unpredictable ability of the regulatory process; regulatory extensions in the United States and in foreign countries; and the effects of COVID-19 on the company’s clinical systems and business operations. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the occasions and cases reflected in the forward-looking statements will occur or occur, and that the timing of the actual occasions and cases and effects may also simply . to differ. materially from those projected in the forward-looking statements. Therefore, you deserve not to place undue reliance on such forward-looking statements. All such statements refer only as of the date they are made and the company does not adopt publicly updating or revising any forward-looking statements, whether as a result of new information, long-term occasions or otherwise.
MEDIA CONTACT: Sheryl SeapyW2O Natural 1-213-262-9390sseapy@naturalcommunications. com